1. Treatment of chronic hepatitis C in a patient with Fanconi anaemia
- Author
-
Tadeusz Wojciech Łapiński, Anna Parfieniuk-Kowerda, Magdalena Rogalska-Płońska, and Robert Flisiak
- Subjects
Adult ,Risk ,medicine.medical_specialty ,Time Factors ,Genotype ,Malignancy ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,Granulocyte Colony-Stimulating Factor ,Ribavirin ,medicine ,Humans ,Adverse effect ,Past medical history ,business.industry ,Bone marrow failure ,Interferon-alpha ,General Medicine ,Hepatitis C, Chronic ,Viral Load ,medicine.disease ,medicine.anatomical_structure ,Fanconi Anemia ,Phenotype ,Treatment Outcome ,chemistry ,Hematologic disease ,Immunology ,Female ,Bone marrow ,business ,Viral load - Abstract
Fanconi anaemia is a rare autosomal recessive disorder with progressive bone marrow failure and predisposition to malignancy. We report a case of a 26-year-old female patient with Fanconi anaemia and severe chronic active hepatitis C virus infection. Her past medical history included treatment with multiple blood transfusions and bone marrow transplantation at the age of 13. The decision to treat the infection was taken, and history of hematologic disease contributed to the introduction of therapy with leukocyte interferon-α n3 and ribavirin combined with a granulocyte - colony stimulating factor. The treatment was well tolerated and after 48 weeks a reduction of the viral load and alanine aminotransferase activity were achieved. No adverse effects on bone marrow functioning were noted.
- Published
- 2011